Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „guselkumab“
Suchtreffer
Begriffe & Kennungen
Tremfya · 4.5 · In psoriasis studies, the safety and efficacy of guselkumab in combination with immunosuppressants, including
Eintrag öffnenTremfya · 4.5 · In psoriasis studies, the safety and efficacy of guselkumab in combination with immunosuppressants, including
Eintrag öffnenTremfya · 4.5 · In psoriasis studies, the safety and efficacy of guselkumab in combination with immunosuppressants, including
Eintrag öffnenTremfya · 4.5 · In psoriasis studies, the safety and efficacy of guselkumab in combination with immunosuppressants, including
Eintrag öffnenTremfya · 4.5 · In psoriasis studies, the safety and efficacy of guselkumab in combination with immunosuppressants, including
Eintrag öffnenTremfya · 4.8 · 117 reactions was 1.6% and 2.4% in the guselkumab q8w and q4w groups respectively. Overall, the rate of inject
Eintrag öffnenTremfya · 4.8 · 118 (n=3) had antibodies that were classified as neutralising antibodies, which equates to 1% of guselkumab tr
Eintrag öffnenTremfya · 4.8 · 146 reactions was 1.6% and 2.4% in the guselkumab q8w and q4w groups respectively. Overall, the rate of inject
Eintrag öffnenTremfya · 4.8 · 147 (n=3) had antibodies that were classified as neutralising antibodies, which equates to 1% of guselkumab tr
Eintrag öffnenTremfya · 4.8 · 73 Phase III analyses in patients with psoriasis, approximately 15% of patients treated with guselkumab develo
Eintrag öffnenTremfya · 4.8 · 8 In the Phase III paediatric study, 18% (n=21) of paediatric psoriasis patients treated with guselkumab devel
Eintrag öffnenTremfya · 4.8 · Immunogenicity The immunogenicity of guselkumab was evaluated using a sensitive and drug-tolerant immunoassay.
Eintrag öffnenTremfya · 4.8 · Immunogenicity The immunogenicity of guselkumab was evaluated using a sensitive and drug-tolerant immunoassay.
Eintrag öffnenTremfya · 4.8 · Immunogenicity The immunogenicity of guselkumab was evaluated using a sensitive and drug-tolerant immunoassay.
Eintrag öffnenTremfya · 4.8 · Immunogenicity The immunogenicity of guselkumab was evaluated using a sensitive and drug-tolerant immunoassay.
Eintrag öffnenTremfya · 4.8 · Immunogenicity The immunogenicity of guselkumab was evaluated using a sensitive and drug-tolerant immunoassay.
Eintrag öffnenTremfya · 4.8 · In the Phase III paediatric study, 18% (n=21) of paediatric psoriasis patients treated with guselkumab develop
Eintrag öffnenTremfya · 4.8 · Injection site reactions In two Phase III psoriasis clinical studies through Week 48, 0.7% of guselkumab injec
Eintrag öffnenTremfya · 4.8 · Injection site reactions In two Phase III psoriasis clinical studies through Week 48, 0.7% of guselkumab injec
Eintrag öffnenTremfya · 4.8 · Injection site reactions In two Phase III psoriasis clinical studies through Week 48, 0.7% of guselkumab injec
Eintrag öffnen